Biomea Fusion (BMEA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Interim CEO called the meeting to order, welcomed shareholders, and introduced directors and officers.
Meeting held in accordance with bylaws and Delaware law; formal business outlined in the notice and proxy statement.
Independent auditors and legal counsel were present for the meeting.
Corporate governance
Record of stockholders as of April 13, 2026, was available for inspection prior to the meeting.
Louis D. Larson appointed as Inspector of Election to oversee and tabulate voting results.
Quorum confirmed with a majority of shares represented in person or by proxy.
Board and executive committee updates
Two nominees, Rainer M. Erdtmann and Eric Aguiar, MD, were nominated for Class II Director positions for a three-year term.
No stockholder nominations for directors were received; nominations declared closed.
Latest events from Biomea Fusion
- Novel oral therapies show promise for diabetes and obesity with key Phase II data ahead.BMEA
Corporate presentation - Icovamenib and BMF-650 show promise for durable diabetes and obesity treatment innovation.BMEA
Corporate presentation - Net loss narrowed, but liquidity concerns persist as cash runway extends only into Q2 2027.BMEA
Q2 2026 - Promising diabetes therapies advance with pivotal data and partnership-driven development ahead.BMEA
Piper Sandler 37th Annual Healthcare Conference - Phase II diabetes and obesity trials advance, with key data expected in the next 12 months.BMEA
Jefferies Global Healthcare Conference 2026 - Icovamenib and BMF-650 show promise for durable diabetes and obesity treatment breakthroughs.BMEA
Corporate presentation - Icovamenib and BMF-650 advance in trials, targeting diabetes and obesity with novel mechanisms.BMEA
H.C. Wainwright 4th Annual BioConnect Investor Conference - Icovamenib achieved robust HbA1c reduction and strong safety in insulin-deficient type 2 diabetes.BMEA
Study Result - BMF-500 demonstrated early efficacy and strong safety in relapsed/refractory acute leukemia.BMEA
Study Update